Success Stories: National Interest Waiver Approval Won without RFE for a Clinical Assistant Professor in Pathology from Pakistan
Client’s Testimonial:
“Thank you for your help and time during the I-140 filing process.”
On March 28th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Clinical Assistant Professor in the Field of Pathology (Approval Notice).
General Field: Pathology
Position at the Time of Case Filing: Clinical Assistant Professor
Country of Origin: Pakistan
State of Residence at the Time of Filing: Florida
Approval Notice Date: March 28th, 2022
Processing Time: 3 months, 12 days
Case Summary:
“[The client’s] research is significant as it substantially improves the ability of clinicians to make effective decisions on the treatment of prostate cancer in order to reduce the rate of overtreatment. Because radical prostatectomy is a major surgery with a meaningful morbidity rate, it is critical that it is only utilized as necessary to prevent prostate cancer-related death. [Client’s] groundbreaking work provides a new and effective method of differentiating clinically significant cancers from clinically insignificant cancers.”
A statement like the above makes certain that the import of one’s research is driven home, which is especially needed when one wants to prove that the work done by a researcher is of national or global interest. The statement was issued by an expert in pathology who wanted to support our NIW (National Interest Waiver) client from Pakistan. As an expert in the field of pathology, her proposed endeavor was to work on identifying novel diagnostic and prognostic features in medical and neoplastic conditions of the gastrointestinal tract, pancreas, and liver. She wanted to improve the treatment strategies and health outcomes associated with cancers and other major pathologies in these areas.
Even before we signed the retainer with her, our team already knew how to proceed with her case. So we gathered some information pertaining to her academic and professional background. This is as follows:
- Her research is relevant to improving the diagnosis and treatment of lung cancer and liver cancer.
- Her research is of great importance because it helps improve treatments for lung cancer, particularly small-cell lung cancer.
- Her work on this topic benefits the treatment of gastrointestinal diseases as well, as her work has identified clinical characteristics and diagnostic markers of liver cancer and gastric heterotopia.
- Her research has led to effective methods to diagnose hepatocellular carcinomas and other tumors at their early stages. As such, her work is invaluable to the national interests of the United States as they relate to the national treatment and reducing the burden of liver cancer.
- She has completed at least 3 reviews to date.
- Her research has resulted in 11 peer-reviewed journal articles (3 of them first-authored).
- These publications have been cited a total of 205 times according to Google Scholar.
- She has pursued research directly related to her proposed endeavor of identifying novel diagnostic and prognostic features of gastrointestinal diseases in order to improve the treatment and outcomes of these conditions for 7 years.
- She is in a position that is narrowly tailored to her unique skill set.
- She has received 2 letters of recommendation from other experts in her field.